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ABSTRACT 
 
Obesity is a disorder that consists of many factors, which has become a global epidemic since it is associated with various 
crucial diseases, such as diabetes, cardiovascular diseases, hypertension, stroke, sleep apnea, as well as other conditions. 
In order to manage obesity, a variety of strategies are taken into account in order to direct attention on those with current 
weight problems as well as those that are at a high risk of developing obesity. Therefore, obesity prevention should be 
focused during the early ages as there is a high risk of developing it in the later years. This article focuses on the risk 
factors of obesity as well as many preventive treatment options for obesity. 
 
Keywords: Obesity, Sleep Apnea. 
 
 
INTRODUCTION 
 
Obesity is defined as the body mass index equal to 
or greater than 30 and less than 40, severe obesity is 
when the BMI is greater than or equal to 40, and 
being overweight is when the BMI is equal to or 
greater than 25 and less than 30.[1,2] Obesity has been 
declared an epidemic and is a major global problem 
among both men and women. In the U.S. one third 
of the adults are obese, which is the leading cause of 
preventable death.[3-5] Worldwide prevalence of 
obesity and overweight increased from 29% in 1980 
to 37% in 2013 among adult men and women.[4] If 
the linear trend continues, then 51% of US adults 
will be obese by 2030 with 130% increase in severe 
obesity.[1] Obesity is associated with increased risk 
of diabetes mellitus, cardiovascular diseases, 
hypertension, hyperlipidemia, stroke, arthritis, 
obstructive sleep apnea, and many other diseases.[3,4] 
The prevalence of childhood and young adult obesity 
is significantly increasing due to unhealthy life style 
habits, and decrease in physical activity that is 
influenced by parental sedentary life style.[2,5] The 
estimated cost of obesity in the USA is more than 
$147 billion annually.[1,3] 
 
Complications of Obsesity 
Firstly, Type 2 diabetes is a severe risk for obese 
individuals. In a study by Daosi et al., of 3,637 
patients, 86% of the obese patients had type 2 
diabetes.[6] Type 2 diabetes and obesity are directly  
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correlated because insulin resistance leads to raised 
blood glucose levels which in turn increases the 
adipose tissue fat.[7] Body fat is divided into 80% 
subcutaneous fat and 20% visceral fat of the total.[7] 
However, visceral fat is a greater contributor to 
obesity since visceral fat cells are correlated to the 
excessive production of adipocytokines which 
causes inflammation and insulin resistance.[7] The 
adipocytes in the visceral tissue have a higher rate of 
lipolysis, which is the breakdown of fats into fatty 
acids compared to the subcutaneous fats. Obesity 
leads to the release of excessive fatty acids from an 
increase in lipolysis.  The increase in fatty acid 
(lipotoxicity) causes insulin receptor dysfunction 
leading to insulin resistance.[7] In normal individual, 
blood sugar levels don't rise, as insulin will turn 
down gluconeogenesis, while individuals with 
insulin resistance, the blood sugar levels continue to 
increase because gluconeogenesis continues.[7] The 
rapid increase in the number of people with type 2 
diabetes is directly correlated to weight gain and 
obesity. 
Along with type 2 diabetes, cardiovascular disease is 
another risk for obese individuals. Cardiovascular 
disease (CVD) is a heart condition that involves 
diseased vessels, structural problems, and blood clots 
and is the leading cause of death worldwide except 
in Africa.[8] According to Bacha, longitudinal studies 
in adults show that obesity is a risk factor for 
coronary heart disease and heart failure; an 
increment of 1 unit of body mass index increases the 
risk by 5% for men and 7% for women.[9] Adipose 
tissue is surrounded by an extensive capillary 
network, and after a meal, the adipose tissue blood 
flow increases. Adipose tissue is what makes up a 
majority of the total body weight, and a big amount 
of fluid can be seen in the interstitial space of the 
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adipose tissue. This large amount of fluid plays a 
vital role in obese individuals that have 
cardiovascular diseases if the volume is redistributed 
into the circulation. Blood flow in the adipose tissue 
is adjusted by beta-receptors that cause 
vasodilation;[10] therefore, the fluid in the interstitial 
compartment is not attainable. Although cardiac 
output increases with total mass fat, the insertion in 
adipose tissue decreases with increasing obesity. 
Generally, for obese individuals, the cardiac 
workload is greater, which causes ventricular and 
atrial chamber dilation and cardiomyopathy. The 
most frequent death in obese individual is due to 
dilated cardiomyopathy that causes fatal arrhythmia, 
where the heart does not beat properly.[10] As was 
seen with type 2 diabetes, there is a strong 
correlation between obese patients who suffer from 
cardiovascular disease. 
Hypertension is the most common health problem 
related to obesity.[11] It is roughly two times as 
prevalent among the obese population compared to 
the non-obese population.[11] White coat 
hypertension, confirmatory ambulatory blood 
pressure parameters, and nondipping blood pressure 
was higher in overweight and obese people in 
comparison to normal weight individuals.[12] 
Abnormal renal sodium and water reabsorption, 
impaired pressure natriuresis, and activation of the 
sympathetic nervous system which plays a major 
role in obesity-related hypertension. Obese 
individuals have higher day and nighttime heart rate 
variability, and impaired decrease in blood pressure 
at night compared to normal weight individuals.[12] 
Juonala et al found that obese children were more 
likely to have hypertension, diabetes type 2, 
cardiovascular diseases, elevated low-density 
lipoprotein levels, and low high-density lipoprotein 
levels. However, obese children who developed into 
adult normal weight will have significant lower 
cardiovascular risk.[29] 
 
Treatment Options 
Obesity is a severe, enduring medical condition, 
which leads to various conditions that are life 
threatening. In fact, it is continuing to increase 
rapidly worldly which is quite debilitating. 
Therefore, in order to control the obesity rates, there 
are many rational strategies that overcome the 
foremost issues associated to the prevention of: 
I.) Normal weight individuals that are 
developing into over weight 
II.) Overweight individuals who are 
becoming obese 
III.) Individuals that used to be overweight 
or obese and are regaining weight and 
IV.) An established condition that is 
becoming worse.[1] 
Helpful management strategies must be integrated in 
order to help solve the issues. The evaluation of 
obesity must be completed frequently by the 
measuring the BMI, measuring the waist 
circumference, etc. in order to gauge risk factors. 
Based off of the evaluation, the designated treatment 
will be recommended. Treatments involve lifestyle 
modification, such as diet modification and 
increased physical activity, behavioral therapy, 
pharmacology therapy, and bariatric surgery. 
 
Lifestyle Modification 
Diets, such as high protein and low carbohydrate 
diets, very low fat diets, very low calorie diets, on 
line weight loss diets, Mediterranean diets, balanced 
nutrient diets, and portion controlled diets are 
effective and induce weight loss.[13]  
In two major studies the DPP and Look AHEAD, 
body weight reduction on an average of 5-10 kg 
occurs mainly in first 6 months.  Also significant 
improvement in lipid levels and blood pressure were 
observed.[13] 
The Framingham Nutrition study focused on diet 
quality, which revealed that a lower quality diet 
(higher nutritional risk scores) were at a greater 
likelihood to become overweight or obese.[3] 
Decreasing the daily caloric intake by 500 
kilocalories leads to a decrease in body weight 
between 5-10 % and a decrease in body mass index 
(BMI) by 2.0 and 2.9 kg/ m2.[14] All diet plans help 
weight loss and no one diet is superior, but the 
important thing is to adhere to the diet, and the 
negative energy balance through restriction of 
calories, which helps achieve weight loss.[13,15] 
One change in lifestyle is participating in physical 
activity to reduce sedentary behavior.[2] Evidence 
shows that participating in adequate physical activity 
improves various factors, such as energy balance, 
maintains weight after weight loss, increases 
sensitivity to insulin, enhances beta-cell function, 
and regulates both blood pressure and cholesterol.[16] 
Rigorous, medium to high intensity workouts have a 
more significant impact on weight loss compared to 
slow walking. In order to reduce the risk of chronic 
disease, exercising about thirty minutes per day is 
sufficient, however, to maintain healthy weight or 
lose weight, at least an hour per day is necessary. 
Due to sedentary life style, non-exercise activity 
thermogenesis (NEAT) is significantly declined. 
Modification of sedentary life style by climbing 
stairs instead of using elevators, walking after a 
meal, parking away from the work place, doing work 
while standing etc. will prevent overweight and 
obesity.[17] 
 
Behavioral Therapy 
Lifestyle changes by reducing calorie intake and 
increasing physical activity can result in about 10% 
loss of initial body weight. To fortify behavioral 
therapy for management of obesity is to assist a shift 
from maladaptive eating and exercise patterns to 
healthy eating and regular exercise. The behavioral 
therapy factors are self-monitoring, stimulus control, 
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goal setting, social support, slower eating, behavioral 
contracting, increase physical activity and education.  
Self-monitoring includes keeping daily records of 
food intake and exercise that helps recognize the 
personal behavior. Stimulus control modifies the 
physical environment by purchasing high fiber diet, 
avoiding fast foods, not keeping unhealthy and high 
calorie foods in the house, and avoiding sweetened 
drinks.[18-21] 
A weight loss study includes an initial phase (3-6 
months) group meeting, which is followed by a 
maintenance phase (6-12 months) where participants 
who received behavioral intervention revealed a 
weight loss of 10.6% in the initial phase and 8.6% in 
the follow up phase.[18] 
Perri and colleagues concluded that individuals who 
attended every other week group maintenance 
sessions for the year after the weight reduction, 
maintained 13.0 kg of their 13.2 kg end of treatment, 
but those who did not receive therapy maintained 
only 5.7 kg of 10.8 kg loss.[19] 
 
Pharmacology Therapy 
National Institutes of Health suggested that every 
individual begins treatment with diet modification, 
exercise, and behavioral therapy. Pharmacotherapy 
is the next step if these lifestyle changes do not 
foster a weight loss equivalent to 10 % of initial 
weight or at least 0.5 kg/week over 6 months. 
Pharmacotherapy is recommended for individuals 
with a body mass index (BMI) greater than 30 
kg/m2 or a BMI higher than 27 kg/m2 plus one or 
more associated comorbidities like hypertension, 
dyslipidemia, coronary artery disease, type 2 
diabetes mellitus, or sleep apnea. After initiating 
therapy within the first 4 weeks if the patient does 
not lose at least 2 kg, then the response to that 
medication is low, and the patient should increase 
the dosage, stop the previous drug, or substitute it 
with another type of medication. The medication 
may be continued if significant weight loss occurs 
on a medication or the initial weight loss is 
maintained since it is effective and the side effects 
are endurable.[22] 
Currently the available medications are Orlistat, 
Liraglutide, Naltrexone/Bupropion, Phentermine/ 
Topiramate ER, and Lorcaserin—the Food and Drug 
Administration approve the later 4 in last 4 years for 
chronic weight management. The guidelines setup 
by FDA for approval of weight loss medications is at 
least a 5% mean weight loss after 1 year of 
treatment, in the study at least 35% of the patients 
treated achieved this weight loss goal.[23] 
Orlistat is an inhibitor of gastric and pancreatic 
lipases that result in malabsorption of approximately 
30% of ingested fat. It has no side effects but since 
there is no absorption, it needs derivative fat-soluble 
vitamins to avoid vitamin deficiency. In a 
randomized study, 892 subjects received placebo 3 
times a day or orlistat, 120 mg 3 times a day for 52 
wk. In the first year, subjects that were treated with 
orlistat lost more weight - 8.76kg than placebo 
treated subjects- 5.81 kg. Orlistat leads to important 
reductions in total and low-density lipoprotein 
cholesterol and in systolic and diastolic blood 
pressure.[22] 
Combination of Phentermine a sympathomimetic 
drug and Topiramate an antiepileptic drug has 
demonstrated efficacy in reducing weight by appetite 
suppression, decreased food consumption, increase 
satiety, increase metabolism and altering taste. The 
EQUIP trial evaluated 2 doses of 
phentermine/topiramate ER in patients with obesity. 
The average body mass reduction ranged from 5.1% 
to 10.9% and the responses were dose related. For 
patients taking the maximum dose of 15/92 mg, 
66.7% to 70.0% of patients attained ≥5% weight loss 
and 47.2% to 48.0% of patients attained ≥10% 
weight loss from baseline. Phentermine/topiramate 
ER was also associated with dose-dependent 
progress in systolic and diastolic blood pressure, 
LDL-C cholesterol, HDL-C cholesterol, and 
triglycerides compared with the placebo. 
Contraindications to phentermine-topiramate include 
pregnancy, glaucoma, and hyperthyroidism. 
Phentermine/topiramate ER is an FDA schedule IV 
controlled substance.[23] 
Lorcaserin is a serotonin 2C receptor agonist, which 
has an effect on anorexigenic neurons in the 
hypothalamus, inhibiting appetite stimulation and 
promoting satiety.  Two trials (BLOOM, 
BLOSSOM) included obese or overweight 
individuals without diabetes. The average body mass 
reduction from baseline was 5.8% with the approved 
10-mg, twice- daily dose of lorcaserin, compared 
with a 2.2% average weight reduction in the placebo 
groups. On average, 44.1% of patients attained 5% 
weight loss, and 20.5% of patients attained ≥10% 
weight loss from baseline in the twice-daily 
lorcaserin group, compared with 20.5% and 7.3% of 
placebo patients achieving ≥5% and ≥10% weight 
loss, respectively. Lorcaserin is a serotonergic drug 
and so will cause serotonin syndrome when 
combined with medications that act on 
neurotransmitter, such as selective serotonin 
reuptake inhibitors (SSRIs), selective serotonin-
norepinephrine reuptake inhibitors, or drugs that 
may affect the clearance of serotonin, such as 
lithium, tramadol, or dopamine antagonists. 
Lorcaserin also led to significant reductions in BMI, 
waist circumference and blood pressure.[23] 
The combination of Naltrexone with Bupropion was 
approved in 2014. Bupropion is a dopamine and 
norepinephrine reuptake inhibitor, which is 
commonly used as an antidepressant and for 
cessation of smoking. Naltrexone is an opioid 
receptor antagonist permitted to treat alcohol and 
opioid dependence. Naltrexone and Bupropion 
produce a synergistic effect and act in the 
hypothalamic melanocortin system and the 
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mesolimbic reward system, both regulates food 
intake and body weight. On average, based on ITT-
LOCF data, 52.4% of patients attained ≥5% weight 
loss and 28.3% of patients attained ≥10% weight 
loss from baseline in the high-dose Naltrexone-
Bupropion group, compared with 23.6% and 9.7% of 
patients in the placebo group, respectively. 
Combination naltrexone-bupropion is 
contraindicated in patients who have epilepsy, 
uncontrolled hypertension, and opioid taking 
medications.[23] 
Liraglutide is an injectable long acting glucagon-like 
peptide-1 receptor agonist used to treat type 2 
diabetes. It was found that Liraglutide causes weight 
loss that prompted the drug company to evaluate the 
drug for the treatment of obesity. Liraglutide act in 
the hypothalamus and other brain regions that 
regulate appetite as well as direct effects on the gut 
to reduce food intake via vagal signaling and 
delayed gastric emptying, causing early satiety. The 
SCALE clinical trials were used to document 
liraglutide’s safety and efficiency in the treatment of 
obesity and help the drug gain FDA approval for this 
indication in 2014 at a 3-mg dose, compared to the 
1.8- mg dose used in the treatment of diabetes. In 
these trials, treated patients lost an average of 6.5% 
of their base line body mass after 1 year of 
treatment, compared with a 1.6% reduction in the 
placebo group. Approximately 56% of the active 
treatment patients were able to achieve ≥5% weight 
reduction, with 28% achieving ≥10% weight 
reduction from baseline at 56 weeks, compared with 
23.4% and 7.9%, respectively, in the placebo groups. 
Liraglutide is available only by subcutaneous 
injection, requiring patients to learn and implement 
injection technique.[23] 
Since there is no for sure first-line agent, the 
decision for treatment should be based on individual 
factors.  
 
Bariatric Surgery 
Bariatric surgery should be factored in for all 
patients with a BMI of 40 or higher and in patients 
with a BMI of 35 or higher with obesity-related 
comorbid conditions. Since the bariatric surgery 
requirement of a BMI of 35 or higher was 
established, emerging evidence has supported the 
clinical and cost effectiveness of surgical 
intervention in patients with a BMI of 30 to 35 who 
do not achieve substantial weight and comorbidity 
improvement with nonsurgical methods. However, 
most guidelines (and third-party payers) still support 
withholding surgical intervention until the BMI is 35 
or higher. A multifaceted team with medical, 
surgical, nutritional, and psychiatric ability should 
evaluate candidates.[24,25] 
Bariatric surgical procedures result in reduced 
stomach capacity (restriction), malabsorption of 
ingested nutrients, hormone changes that suppress 
appetite, or a combination of these mechanisms. 
Perioperative mortality risk associated with bariatric 
surgery is low (<0.3%). Weight loss equal to or 
greater than 50% of excess body weight (current 
weight minus ideal body weight) is considered a 
success. Commonly performed bariatric procedures 
include laparoscopic adjustable gastric banding, 
Roux-en-Y gastric bypass, biliopancreatic diversion 
duodenal switch, and sleeve gastrectomy.[24,25] 
Laparoscopic gastric banding, a restrictive procedure 
that forms a minute gastric pouch that consists of an 
adjustable outlet, which is a silicone belt that is lined 
with an  inflatable balloon which is fastened into a 
closed ring that surrounds the upper stomach. The 
band is adjusted (via a port) to achieve early satiety 
without dysphagia. Three to 6 years after gastric 
banding, excess weight loss is 45% to 72%.[24,25] 
Roux-en-Y gastric bypass, a combination restrictive 
and malabsorptive procedure, involves creating a 
small (30 mL) proximal gastric pouch, which is 
separated from the distal side of the stomach and 
joined to the Roux limb of small bowel. Digestion 
and absorption of nutrients occur in the mid-small 
intestine. With Roux-en-Y gastric bypass, stomach 
capacity is reduced, as is absorption of calories. 
Additionally, delivery of nutrients to the mid-small 
intestine triggers hormone changes that suppress 
appetite. Three to 6 years after Roux-en-Y gastric 
bypass, excess weight loss is 62%.[24,25] 
Vertical sleeve gastrectomy is a restrictive procedure 
that requires incision of the greater curvature of the 
stomach. This procedure involves 70% vertical 
gastric resection, which forms an extended, narrow 
tubular gastric reservoir that does not have an 
intestinal bypass component. This procedure reduces 
stomach capacity and suppresses appetite by 
removing tissue that produces ghrelin, a hunger-
stimulating hormone. Excess weight loss 3 to 6 years 
after sleeve gastrectomy is 53% to 77%.[24] 
One of the most inclusive systematic reviews 
examined 136 studies and 22,094 patients which 
underwent bariatric surgery. The review concluded 
with a high trend towards dissimilar weight loss 
outcomes across procedures. Weighted mean 
percentage of excess weight loss (%EWL) was 50% 
(32% to 70%) for adjustable gastric banding, 68% 
(33% to 77%) for Roux¬en-Y gastric bypass, 69% 
(48% to 93%) for vertical banded gastroplasty, and 
72% (62% to 75%) for biliopancreatic diversion 
duodenal switch. Type 2 diabetes rate remission was 
different across procedures. The rate was 48% (29% 
to 67%) for adjustable gastric banding, 84% (77% to 
90%) for Roux¬en¬Y gastric bypass, 72% (55% to 
88%) for vertical banded gastroplasty, and 99% 
(97% to 100%) for biliopancreatic diversion with 
duodenal switch. An identical pattern of disease 
remission was noticed for hypertension, 
dyslipidemia, and obstructive sleep apnea, with the 
greatest  rates of remission seen in patients who had 
went through the  biliopancreatic diversion with 
duodenal switch, followed by Roux¬en¬ Y gastric 
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bypass, vertical banded gastroplasty, and lastly 
adjustable gastric banding.[24] 
High quality data from Randomized Controlled 
Trials have fixed that bariatric procedures are more 
successful compared to the medical or lifestyle 
interventions for inducing weight loss (26kg) and 
remission of type 2 diabetes, advancement in long 
term survival and quality of life, a decreased risk of 
incident cardiovascular disease and diabetes, 
betterment in sleep apnea and osteoarthritis, and long 
lasting improvements in obesity related 
comorbidities between patients who have went 
through  bariatric surgery compared to  non¬surgical 
controls.[24,26-28] 
In the future, bariatric procedures will base on key 
physiological variables that include changes in 
ghrelin, leptin, glucagon like peptide¬1, 
cholecystokinin, peptide YY, gut microbiota, and 
bile acids.[24] 
Patients who undergo bariatric surgery should 
continue dietary, physical activity, and behavioral 
measures and should receive nutrient replacement 
therapy.[25] 
 
CONCLUSION 
 
Obesity is a widespread disease associated with 
multiple comorbid conditions, and so the WHO 
(World Health Organization) has declared obesity a 
global epidemic and NIH (National Institute of 
Health) has clinical guidelines and recommendations 
for management of obesity and overweight. A 
reduction of 10% body weight will have a significant 
beneficial impact on one’s health care cost. It should 
be treated forcefully in the same way that it applied 
to other diseases. The advances in treatment, such as 
life style modification, pharmacology therapy, and 
bariatric surgery will prevent the global problem of 
overweight and obesity. The increase in awareness 
and research will bring about better treatment for the 
obese in the next few years. 
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